Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00987870 | Safety and Efficacy of BFH772 in Psoriasis Patients | PHASE1 | COMPLETED | 15 | — | — | Sep 1, 2009 | - | Mar 28, 2011 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| BFH772 cream 1% | EXPERIMENTAL | - |
| Placebo to BFH772 cream 1% | PLACEBO_COMPARATOR | - |
| BFH772 ointment 1% | EXPERIMENTAL | - |
| Placebo to BFH772 ointment | PLACEBO_COMPARATOR | - |
| calcipotriol/betamethasone ointment | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BFH772 | DRUG | - |
| Placebo | DRUG | - |
| calcipotriol/betamethasone | DRUG | - |
Inclusion Criteria: * Stable mild to moderate plaque psoriasis (BSA involvement \< 10% or PASI \< 10 * Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthri...